CN1940060A - Novel lactic acidophilus and its application - Google Patents
Novel lactic acidophilus and its application Download PDFInfo
- Publication number
- CN1940060A CN1940060A CNA2005101054599A CN200510105459A CN1940060A CN 1940060 A CN1940060 A CN 1940060A CN A2005101054599 A CNA2005101054599 A CN A2005101054599A CN 200510105459 A CN200510105459 A CN 200510105459A CN 1940060 A CN1940060 A CN 1940060A
- Authority
- CN
- China
- Prior art keywords
- lasw
- lactobacterium acidophilum
- bacteria
- cell
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims abstract description 62
- 241000607142 Salmonella Species 0.000 claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 17
- 210000004185 liver Anatomy 0.000 claims abstract description 10
- 210000000952 spleen Anatomy 0.000 claims abstract description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 7
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 7
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 6
- 244000052616 bacterial pathogen Species 0.000 claims description 24
- 230000000968 intestinal effect Effects 0.000 claims description 23
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 21
- 208000015181 infectious disease Diseases 0.000 abstract description 13
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 4
- 238000001179 sorption measurement Methods 0.000 abstract description 4
- 239000003674 animal food additive Substances 0.000 abstract description 2
- 241000607768 Shigella Species 0.000 abstract 1
- 241000295644 Staphylococcaceae Species 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 230000007661 gastrointestinal function Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000013618 yogurt Nutrition 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 36
- 235000014655 lactic acid Nutrition 0.000 description 25
- 239000007788 liquid Substances 0.000 description 20
- 230000012010 growth Effects 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 238000004140 cleaning Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 239000007853 buffer solution Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000000274 adsorptive effect Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229940099352 cholate Drugs 0.000 description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 4
- 239000006059 cover glass Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 3
- 241001468157 Lactobacillus johnsonii Species 0.000 description 3
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000057717 Streptococcus lactis Species 0.000 description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000021262 sour milk Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241001333951 Escherichia coli O157 Species 0.000 description 2
- 241000272496 Galliformes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 241001655322 Streptomycetales Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001071864 Lethrinus laticaudis Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种新颖的嗜酸乳杆菌LASW，其具有优良的耐动物消化液的特性，并对大肠杆菌、沙门氏菌、志贺氏菌、金黄色葡萄球菌和其它葡萄球菌具抑制作用。此外，其对人类及动物的肠道上皮细胞均具有良好的吸附性，并可抑制细菌侵入动物肠道上皮细胞中，因而降低细菌移转至肝及脾脏造成的感染。本发明的嗜酸乳杆菌可适用于酸奶、生菌剂、饲料添加剂产品中，具有调整动物肠胃功能的优良效果。
The present invention relates to a novel Lactobacillus acidophilus LASW, which has excellent resistance to animal digestive juices and has inhibitory effects on Escherichia coli, Salmonella, Shigella, Staphylococcus aureus and other staphylococci. In addition, it has good adsorption to intestinal epithelial cells of humans and animals, and can inhibit bacteria from invading animal intestinal epithelial cells, thereby reducing infections caused by bacteria transferring to the liver and spleen. The Lactobacillus acidophilus of the present invention can be applied to yogurt, probiotics, and feed additive products, and has an excellent effect of adjusting the gastrointestinal function of animals.
Description
Technical field
The present invention relates generally to a kind of Lactobacterium acidophilum (Lactobacillus acidophilus) of novelty and uses.Particularly, Lactobacterium acidophilum of the present invention has the characteristic of the good liquid of anti-the animal digestion, can survive in the animal intestine gastropore and suppresses growth of pathogenic bacteria.Lactobacterium acidophilum of the present invention can be applicable in sour milk, bacteria-promoting agent, the feedstuff additive product, has the excellent results of adjusting the animal functions of intestines and stomach.
Background technology
Milk-acid bacteria is human and the main flora of animal intestinal, is usually used in the humans and animals probiotic products.One of its salubrious main mode is for suppressing the growth (Lehto et al., 1997) of pathogenic bacteria (as Salmonellas or intestinal bacteria etc.) in the intestines; Also have to studies show that milk-acid bacteria can prevent the invasion of pathogenic bacteria, invade epithelial cell (Jinet al., 1996) as the Corynebacterium diphtheriae (Salmonella typhimurium) that can prevent salmonella.But, must consider two fundamental characteristics if milk-acid bacteria is wanted and can middlely in animal body bring into play above-mentioned functions: the firstth, can milk-acid bacteria stand animal intestine gastropore Digestive tract secreted hydrochloric acid in gastric juice and cholate, survives and arrive enteron aisle; Second is the adsorptive power of milk-acid bacteria to animal host's intestinal epithelial cell.The ability of milk-acid bacteria absorption mucous membrane surface, be that it can be in the condition (Rammelsberg and Radler, 1990) of human intestines and stomach and pathogenic bacteria competitive adsorption, because pathogenic bacteria is caused the prerequisite of infection, also be to be adsorbed in intestinal cell (Chou and Weimer, 1999).General this characterization of adsorption is the absorption situation of using between extracorporeal mode research thalline and the intestinal cell strain (Marteau et al., 1997), as Int-407 (Leung and Finlay, 1991) and Caco-2 (Conway et al., 1987; Marteau etal., 1997) cell strain, carry out the research of milk-acid bacteria absorption and competition excluding pathogenic bacteria.
Salmonella can cause food poisoning (Boonmar et al., 1998) as Corynebacterium diphtheriae, and in recent years, the Corynebacterium diphtheriae bacterial strain of tool multiple drug resistance increases (Boonmar et al., 1998 year by year; Gross et al., 1998), and also occurred the fluoroquinolones of new generation (fluoroquinolones) and the third generation are extensively imitated the head-germ spore element drug-fast bacterial strains of third generation biocide tool such as (cephalosporins), when becoming Salmonella infection, on the clinical treatment one big problem (Herikstad et al., 1997; Amyes and Gemmell, 1997; Piddock, 1998).Therefore, the scholar will treat pathogenic bacterial infection and transfer the use probiotic bacterium to, strengthen the intestinal mucosa defense mechanism, and the protection enteron aisle avoids the infection (Nird and Edlund.1990) of pathogenic bacterias such as Salmonellas.
At present existing many milk-acid bacterias can suppress the correlative study of pathogenic bacteria, are disclosed in patent documentation or the academic journal.For example United States Patent (USP) the 5th, 603, discloses the adsorbable Caco-2 cell of Lactobacillus johnsonii (Lactobacillusjohnsonii) bacterial strain CNCM I-1225 in No. 930, and suppress the absorption that enterotoxin and intestines are invaded pathogenic bacteria; United States Patent (USP) the 3rd, 953, disclose the growth that lactobacillus lactis (Lactobacilluslactis) bacterial strain NRRL B-5628 can suppress bacterium in other Digestive tract (as mouth or stomach) for No. 609, can be used on piggy and the diarrhoea of other new birth animal or the treatment of intestinal colic especially, reduce the growth of intestinal bacteria (Escherichia coli) or coliform; United States Patent (USP) the 6th, disclose Lactobacterium acidophilum (Lactobacillus acidophilus) bacterial strain HY2177 and lactobacterium casei (Lactobacilluscasei) bacterial strain HY2743 for 491, No. 956 and can prevent and treat gastritis and duodenum and the stomach ulcer that the Helicobacter pylori infection is caused; United States Patent (USP) the 4th, 874 discloses Bacterium lacticum No. 704 can produce a kind of antimicrobial substance, can be suppressed at the growth of the spoilage organism (as special bacterium of Li Shi and Salmonellas) in the pathogenic bacteria and food under the refrigerating temperature; United States Patent (USP) the 5th, 340,577 and 5, disclose the growth that Bacterium lacticum, Lactococcus lactis (Lactococcus lactis), Fo Shi citric acid bacillus (Citrobacter freundii), faecalis (Enterococcus), bifidus bacillus (Bifidobacterium) and bacterium acidi propionici (Propionibacterium) can suppress Salmonellas 604, No. 127; U.S. Patent Publication discloses Lip river moral Bacterium lacticum (Lactobacillus reuteri), Lactobacillus johnsonii and Bacillus subtilus (Bacillus subtilis) for No. 20020018770 can be applied to suppress in the chicken feed pathogenic bacteria growth, and the growth of promotion poultry, and then the usage quantity of minimizing microbiotic or medicament; U.S. Patent Publication discloses Bacterium lacticum No. 20040028665 and propionibacterium freudenreichii (Propionibacterium freudenreichii) uses simultaneously, can suppress Escherichia coli O 157: the growth of H7 type and other pathogenic bacteria; U.S.'s publication application discloses a kind of lactobacterium casei for No. 20040029127 can strengthening immunity, and then suppresses growth of pathogenic bacteria; U.S.'s publication application discloses a kind of lactobacillus salivarius (Lactobacillus salivarius) for No. 20040038379, it has the characteristic of similar ablastins, can suppress listeria bacteria and staphylococcus, comprise anti-methicillinum streptococcus aureus (MRSA) and bacillus, and can not suppress other Bacterium lacticum; U.S.'s publication application discloses lactobacillus fermentum (Lactobacillus fermentum) bacterial strain ME-3 No. 20040151708, be a kind of tool germ resistance and oxidation resistant probiotic bacterium, can suppress Shigellae (Shigella sonnei), streptococcus aureus, Corynebacterium diphtheriae and Hp (Helicobacter pylori) in intestinal bacteria, the Song.
Academic journal also is seen in many for correlative study and the effect thereof of milk-acid bacteria, for example lactobacillus bifidus can prevent to produce the Escherichia coli O 157 of shiga toxin (shiga toxin-producing) in the mouse test: and the infection of H7 type (Asahara et al., Infect.Immun.72:2240-2247); Lactobacillus rhamnosus (Lactobacillus rhamnosus) can reduce the infection (Hirano, et al., Microbiol Immunol.47:405-409) of Enterohemorrhagic E.coli; Bacterium lacticum and lactose can suppress Salmonellas propagation (Johannsen et al., Avian Dis.48:279-286); Lip river moral Bacterium lacticum can suppress listeria monocytogenes (Listeria monocytogenes) and Salmonellas growth (Kuleasan et al., Nahrung., 46:408-410); The absorption element that bifidobacterium adolescentis (Bifidobacterium adolescentis) bacterial strain 1027 is produced, can compete inhibition enterotoxigenic Escherichia coli, enteropathy originality intestinal bacteria and clostridium (Clostridium difficile) and be attached to intestinal epithelial cell strain Lovo (Zhonget al., World J.Gastroenterol., 10:1630-1633); De Shi milk-acid bacteria (Lactobacillusdelbrueckii subsp.lactis) in meat product, can suppress pathogenic bacterium and spoilage organism growth (Senne etal., J.Food Prot., 66:418-425); Lactococcus lactis (Lactococcus lactis subsp.lactis) ATCC 11454 strains have antibacterial ability (Millette et al., J.Food Prot., 67:1184-1189); The supernatant liquor of Bacterium lacticum LB obviously reduced Salmonellas to the intrusion of intestinal cell Caco-2/TC-7 (Coconnier et al., Appl.Environ.Microbiol., 66:1152-1157); The bacterium liquid of lactobacterium casei and discarded culture supernatants thereof all can suppress Salmonellas and invade intestinal cell Caco-2, but when pH 7, lose its effectiveness, and mouse was through continuous feeding L.casei GG 7 days, can after infecting Salmonellas, keep 100% survival rate, and reduced bacterium number (Hudault et al. in liver and the spleen, Appl.Enviro.Microbiol., 63:513-518); The feeding lactobacterium casei can be mouse and provides protection to intrusion and the infection of Salmonellas, and think the IgA of this provide protection and intestinal secretion relevant (Perdigon et al., Journal of Dairy Research, 57:255-264); In the Salmonella infection mouse test of sublethal dose, whole course of infection can be divided into three periods, and be to breed period at internal organs such as liver and spleens after Salmonellas is invaded first period, after a week, entered for second period, Salmonellas propagation stops, and reaches the peak period of the highest bacterium number, and also continue a week in this period, in the 3rd period, the bacterium number of Salmonellas in liver and spleen descend gradually (Nauciel et al., Infection and Immunity, 60:450-454).
In addition, also existing many report research milk-acid bacterias suppress the mechanism of Salmonellas.Fuller (1986) once proposed to utilize does not have a bacterial classification of adsorptive power, as dried suis (Streptococcus faecium), because the speed of its propagation surpasses the rate of discharge of chyme, and can survive in enteron aisle, therefore the bacterial classification that has this characteristic can stay in the large intestine mucous layer, and needn't be adsorbed on the epithelial cell.Scholar (Hormaeche et al., 1980 are arranged in addition; Van Dissel et al., 1985) propose the propagation of the Salmonellas that infects in the host, the initial stage is the effectiveness that suppresses by the function performance after scavenger cell and the activation thereof.The mechanism that milk-acid bacteria suppresses the enteric microorganism infection is competitive the eliminating, comprises competition, secretion antibacterial substance (Hudault et al., Applied and EnvironmentalMicrobiology, 63:513-518 to nutrient and intestinal cell absorption position; Chauviere et al., FEMS Microbiology Letters, 91:213-218) and the activation intestinal tract immune system, can improve ability (Perdigonet al., Journal of Dairy Research, 57:255-264 that the host suppresses pathogenic bacteria; Schiffrin et al., AmericanJournal of Clinical Nutrition, 66:515S-520S).
Summary of the invention
The present invention is from chitling road screening and separate a strain Lactobacterium acidophilum, and it has the fundamental characteristics of the above-mentioned mankind and animal probiotic bacterium, and can resist pathogenic bacteria, invades and infect the effect of intestinal mucosa and liver, spleen organ as Salmonellas.Lactobacillus acidophilus strains of the present invention can be applicable in the fodder additives of sour milk and domestic animals and fowls, uses as bacteria-promoting agent, promotes the intestines and stomach function of animal.
Therefore, one aspect of the present invention provides a kind of Lactobacterium acidophilum LASW, and preserving number is CCTCCNO:M204083, is preserved in Chinese typical culture collection center.
Further aspect of the present invention provides a kind of probiotic composition, and it comprises above-mentioned Lactobacterium acidophilum LASW.
Another aspect of the invention provides a kind of feed composition, and it comprises above-mentioned Lactobacterium acidophilum LASW.
Another aspect of the invention provides a kind of medical composition that is used to prevent or treat pathogenic bacterial infection, and it comprises above-mentioned Lactobacterium acidophilum LASW.
Description of drawings
Fig. 1 shows that intestinal bacteria are subjected to the inhibition growth test result of Lactobacterium acidophilum supernatant liquor of the present invention (SCS).
Fig. 2 shows that Salmonella choleraesuls are subjected to Lactobacterium acidophilum of the present invention to suppress to invade test-results.
The mouse that Fig. 3 shows LASW and blank group general blood serum IL-6 of the 3rd and the 6th day behind the feeding Salmonellas changes.
Embodiment
The present invention relates generally to a kind of Lactobacterium acidophilum LASW of novelty, is preserved in Chinese typical culture collection center on November 17th, 2004, and preserving number is CCTCC NO:M204083.This Lactobacterium acidophilum has following characteristic:
1. filter out from chitling road, native country, Taiwan;
2. have an ability of excellent acid and bile tolerance, can be by surviving in the enteron aisle behind the gastro-intestinal digestion liquid in the mankind and animal body;
3. have the good mankind and animal intestinal epidermic cell adsorptive power;
Can with enteric bacterial pathogens competition absorption to intestinal cell, and then the inhibition enteric bacterial pathogens, as intestinal bacteria, Salmonellas, Shigellae, streptococcus aureus and other staphylococcic absorption growth with invade intestinal cell and intrusion and be transferred to the effect of liver and spleen.
Based on above-mentioned characteristic, lactobacillus acidophilus strains LASW of the present invention can be applicable to sour milk and domestic animals and fowls feed additive in, use as bacteria-promoting agent, promote the intestines and stomach function of animal.In addition, Lactobacterium acidophilum of the present invention also can be applicable in the medical composition, in order to prevention or treatment pathogenic bacterial infection.
The following example is in order to illustrating effect of the present invention, but not in order to limit category of the present invention.
Embodiment
One, acidproof and bile tolerance test
With reference to Conway et al., Journal of Dairy Science, the described method of 70:1-12 is carried out acid resistance test.With the LASW lactic acid bacterial liquid (10 of 100 μ l through cultivating
8～10
9The CFU/ milliliter), be added to the phosphate buffer soln that is adjusted to pH 2.0,2.5 and 3.2 through 0.1N HCl, or pig gastric juice (pH 3.2), and under 37 ℃, cultivated 3 hours.Lactobacillus suspension adds pH 7.2 phosphate buffer solns of the same terms and organizes in contrast.Cultivate after behind the serial dilution, be incubated at MRS agar respectively, the milk-acid bacteria bacterium number of calculating survival.
With reference to Gilliland et al., Journal of Dairy Science, the method described in the 73:905-911 is carried out the bile tolerance test.With above-mentioned milk-acid bacteria through the acid resistance test survival, with 5, behind centrifugal 5 minutes of the 000rpm, clean with phosphate buffer soln (pH 7.2), again milk-acid bacteria is moved in 9 milliliters the MRS nutrient solution and (contain and do not contain the cholate (Sigma) of 0.3%w/v respectively, cultivated 3,12 and 24 hours, and cultivated after serial dilution, tipping is incubated at the lactic acid bacteria number of MRS agar counting survival.
Test-results shows, Lactobacterium acidophilum LASW of the present invention, and its bacterium number reduces by 2 logarithmic value (reducing to 8.5 from 10.5) after pH 2.0 environment are cultivated 3 hours down; At pH 2.5 and the next stable growth of 3.2 environment.After pig gastric juice (pH3.2) is cultivated 3 hours, only reduce by 0.6 logarithmic value.In containing the environment of cholate, cultivate, still can stabilized growth.Show that it has good acid and cholate tolerance.
Two, intestinal cell strain adsorption test
Get one 24 hole porous flat plates, put into a slice cover glass in every hole.The individual cells dihedral culture dish of Int-407 and Caco-2 completely will be cultivated, outwell old nutrient solution, outwell, add 1% trypsinase/EDTA and digest for about 1 milliliter with behind twice in 1 * PBS buffer solution for cleaning dihedral culture dish, pat under the dihedral culture dish number, make cell suspension.Add 40 milliliters of fresh BME (Int-407) or MEM (Caco-2) (all containing FBS and penicillin-Streptomycin sulphate) nutrient solution (promptly diluting 4 times), after shaking up, every hole adds 0.5 ml cells suspension, in 37 ℃, CO
2Cultivate in the gas, make cell adhere to cover glass by merisis.With old nutrient solution sucking-off, every hole adds 0.5 milliliter, 1 * PBS buffer solution for cleaning again, the cell that nutrient solution that eccysis is old and removal are not adhered to, twice of repeated washing.Add 0.5 milliliter of fresh nutrient solution (not containing penicillin-Streptomycin sulphate) that is fit to indivedual different cells, and 100 μ l lactic acid bacterial liquids, in 37 ℃, CO
2Cultivated 2 hours in the gas.
The old nutrient solution of sucking-off, 0.5 milliliter of every hole adding, 1 * PBS buffer solution for cleaning three times are rocked with the 100rpm rotating speed at every turn and were cleaned 5 minutes, with the dropper sucking-off.After adding 200 milliliters of 10% formalin, rock with the 100rpm rotating speed and to fix 30 minutes, make thalline and cell fixation in the hole on the cover glass, and with dropper sucking-off formalin.Add 0.5 milliliter, 1 * PBS buffer solution for cleaning three times, rock with the 100rpm rotating speed at every turn and cleaned 5 minutes.Adding at 24-hole porous culture dish outsourcing layer of aluminum foil paper, is rocked dyeing 5 minute with the 100rpm rotating speed through the Viola crystallina 200 μ l of filter paper coarse filtration dyeing, adds 0.5 milliliter, 1 * PBS buffer solution for cleaning and removes unnecessary stain.Drip 1 * PBS damping fluid on slide glass, take out cover glass with tweezers and be placed on it, avoid dry, observe down, and count the lactic acid bacteria number (Gopalet al., 2001) that adsorbs on each cell with inverted fluorescent microscope (Olympus IMT-2).
Test-results shows that Lactobacterium acidophilum of the present invention reaches the enteron aisle epidermic cell of pig, chicken, rabbit to human intestine's epidermic cell Int-407 and Caco-2 cell, and its adsorptive power all is at least each cell greater than 15 lactic acid bacteria numbers.
Three, the inhibition growth effect of various pathogenic bacteria is tested
Lactobacterium acidophilum of the present invention was cultivated in MRS 24 hours, and the pH value of bacterium liquid reduces to 3.7, and streptococcus aureus, other staphylococcus, intestinal bacteria and Shigellae are carried out sensitivity tests.The result shows that Lactobacterium acidophilum of the present invention all forms the inhibition circle that differs in size to these pathogenic bacterias, really has the effect that suppresses the pathogenic bacteria growth.In addition, in this test with the SCS effect of LASW lactobacillus strain 4 hours; Remarkable to colibacillary inhibition growth action effect, can reduce bacterium several 10
2-10
4CFU/ milliliter (Fig. 1).
Four, suppress the test that Salmonella choleraesuls are invaded intestinal cell strain Int 407
Salmonella choleraesuls (Salmonella Choleraesuis) are the very strong infecting both domestic animals and human cause of disease bacterium of invasive, therefore, select its discussion as the inhibition bacterium intrusion of milk-acid bacteria LASW.This test method mainly is with reference to (1997) described methods such as Hudault.
(1) preparation of milk-acid bacteria
To test lactic bacterium strains takes out from freezing glycerine bottle, activate twice continuously with the MRS substratum, after cultivation overnight under 37 ℃, partly bacterium liquid in 4 ℃ with 6000rpm centrifugal 10 minutes, take out supernatant liquor (spent culture supernatant, SCS), utilize among the 1N NaOH of filtration sterilization and lactic acid bacterial liquid (bacterial culture) and supernatant liquor, prepare above-mentioned adjust with lactic acid bacterial liquid through being adjusted to pH neutral and supernatant liquor to test.
(2) preparation of Salmonella choleraesuls
Salmonella choleraesuls (bacterial strain SCV2a, SCV26a) are incubated in the LB substratum, collect thalline in centrifugal 10 minutes after re-activation is cultivated, and with after the cleaning of sterile phosphate buffered soln, are suspended in the phosphate buffer soln with volume.Bacterium liquid is cultivated in nutritional medium with colony counting method through serial dilution, carries out the counting of viable count.
(3) milk-acid bacteria suppresses Salmonella choleraesuls intrusion test in Int 407 intestinal cell strains
With the intestinal cell Int 407 in the 75T culturing bottle with trypsinase-EDTA digestion process of 1 milliliter after, pat culturing bottle cell taken, be sub-packed in 96-hole trace culture plate, add 1 * 10 in each hole
5Cells/ml, overnight through cultivating, make form monolayer cell after, remove old cell culture medium, add the cell culture medium of 90 μ l antibiotic-frees.Get the lactic acid bacterial liquid and the supernatant liquor (SCS) of preparation among the 10 μ l above-mentioned (1), add in each hole of cell cultures dish, place 37 ℃, 5%CO
2The middle cultivation 1 hour.With (2) described Salmonella choleraesuls suspension, make final concentration be about 10 through suitably taking out 10 μ l after the dilution, adding in each hole
6The CFU/ hole, made the bacterium sedimentation in 10 minutes with the 1000rpm low-speed centrifugal, the cell cultures dish moves to cell culture incubator and cultivates after 1 hour and 2 hours, clean each hole five times with phosphate buffer soln, after remaining in extracellular E.coli and Salmonella choleraesuls thalline with flush away, each hole adds the BME cell culture medium that 100 μ l contain ceftriaxone (ceftriaxone) (100 mcg/ml), place cell culture incubator to leave standstill 1 hour, to kill the outer Salmonella choleraesuls bacterium of Int 407 cell born of the same parents.Clean each hole 5 times with 0.01M PBS again, add after the aseptic triton X-100 of 100 μ l (1%) carry out 10 minutes lysis effect, with the mixed liquid in acutely mixed each hole of micropipet, take out mixed liquid and carry out serial dilution with 0.01M PBS, with the nutritional medium colony counting method, through cultivating 48 hours, counting is invaded Int 407 intracellular Salmonella choleraesuls bacterium numbers.
Can learn that by the result Lactobacterium acidophilum of the present invention after effect in a hour, can reach 10 for the inhibition intrusion of Salmonella choleraesuls
2～10
3The CFU/ milliliter; After 2 hours Salmonella choleraesuls intrusion, can suppress to surpass 10
3CFU/ milliliter (Fig. 2).
Five, measure TNF-α and IL-6 concentration with enzyme-linked immunosorbent assay (ELISA)
Mouse is invaded when infecting by Salmonellas, the cell of first reaction is a scavenger cell, scavenger cell is except that phagolysis, also can secrete some cytohormones, mainly contain TNF-α, IL-1, IL-6, IL-8 and IL-12, these cytohormones can be at local infection function of organization or systemic effect.Scavenger cell is not when being activated, few (the Beutler et al. of the output of TNF-α, 1986), Gram-negative bacteria stimulates scavenger cell (Balkwill et al. with lipopolysaccharide (LPS) usually, 2000), therefore, TNF-α can be as important indicator (the Nauciel and Espinasse-Maes that is subjected to the infection of Salmonellas initial stage, 1992), the TNF-α that produces can activate vascular endothelial cell in local action, increase vascular permeability, IgG, entering of complement and cell discharges TNF-α to whole body if cause liver and spleen scavenger cell, then can cause septicemia, this is that a kind of vasodilation of general causes a large amount of body fluid flow to tissue, cause normal blood to be unable to supply, cause organ failure, be called septic shock.IL-6 is when local infection, but activated lymphocyte and the manufacturing of increase antibody if be released into the manufacturing that acute phase protein then can be had a fever and induce to whole body, cause systematic inflammation (Hirano, 1992).In inflammatory response, TNF-α just increases the amount of its mRNA in 15-30 minute behind irriate, and the time that IL-6 produces is then later, and therefore, the output of measuring TNF-α and IL-6 can be understood the severity of whole inflammatory response.
(1) measures the concentration of TNF-α with enzyme-linked immunosorbent assay
According to Endogen (USA) standard step that company provided is carried out for Woburn, MA.:
The anti-ageing mouse TNF-alpha monoclonal antibodies (1.03 mcg/ml are in adsorption-buffering liquid) of getting 100 μ l adds in the ELISA flat chassis hole, at room temperature leaves standstill (about 14 to 16 hours) overnight and makes it adhere to (coating) to trying to get to the heart of a matter.After removing adsorption-buffering liquid, each hole adds the blocking-up damping fluid (with the analysis buffer filling) of 200 μ l, leave standstill 1 hour under the room temperature after, remove the blocking-up damping fluid, wash gently three times with cleaning buffer solution again.Monoclonal antibody (0.25 mcg/ml) the 50 μ l that get anti-ageing mouse TNF-α vitamin H-mark are in hole, the standard substance or the testing sample (serum after mouse liver grinds) that add 50 μ l again, after leaving standstill 2 hours under the room temperature, fall to remove the mixed liquid in the hole, after cleaning buffer solution cleaning three times, each hole adds the HRP-conjugation streptomycete avidin (streptavidin) (0.125 mcg/ml) of 100 μ l, effect is after 30 minutes under the room temperature, clean five times with cleaning buffer solution, above cleaning step all must be inhaled and be removed remaining liquid with 96 holes trace flat chassis back-off on paper handkerchief after finishing.Last each hole adds 3,3 ', 5 of 100 μ l, 5 '-tetramethyl benzidine (TMB) matrix solution, and the lucifuge effect made in 30 minutes under the room temperature carries out color reaction, adds the 0.18M sulphuric acid soln of 100 μ l at last, the color development stopping reaction.Read under wavelength 450nm, to read light absorption value in ELISA, and according to the concentration of typical curve conversion TNF-α.
2. the making of typical curve
Advise according to the specification sheets that Endogen company provides, with 400 μ l analysis buffer dissolvings TNF-α standard substance (mouse TNF-α ELISA standard substance) (TNF-α standard substance use in back 1 hour in redissolving), making its concentration is the 2450pg/ milliliter, carry out 2 times of serial dilutions with analysis buffer again, measure light absorption value under each concentration TNF-α standard substance wavelength 450nm according to above-mentioned analytical procedure, the result is made into typical curve.
(2) measure IL-6 concentration with enzyme-linked immunosorbent assay
According to Endogen (USA) standard step that provides of company is carried out for Woburn, MA.:
The anti-ageing mouse IL-6 monoclonal antibody (2.5 mcg/ml) of getting 100 μ l adds in the ELISA flat chassis hole, at room temperature leaves standstill (about 14 to 16 hours) overnight, primary antibody is adsorbed to tries to get to the heart of a matter.After removing adsorption-buffering liquid, each hole adds analysis (blocking-up) damping fluid (4%BSA is in PBS) of 200 μ l, leave standstill 1 hour under the room temperature after, remove the blocking-up damping fluid, (50mM Tris, 0.2%Tween-20 pH8.0) wash three times gently with 200 μ l cleaning buffer solutions.The biotin labeled monoclonal antibody of anti-ageing mouse IL-6 (0.25 mcg/ml is in analysis buffer) of getting 50 μ l is in hole, the standard substance or the testing sample (serum of mouse heart blood sampling) that add 50 μ l again, after leaving standstill 2 hours under the room temperature, fall to remove the mixed liquid in the hole, after cleaning buffer solution cleaning three times, each hole adds the HRP-conjugation streptomycete avidin (0.125 mcg/ml is in analysis buffer) of 100 μ l, effect is after 30 minutes under the room temperature, clean five times with cleaning buffer solution, above cleaning step all must be inhaled and be removed remaining liquid with 96 holes trace flat chassis back-off on paper handkerchief after finishing.Last each hole adds 3,3 ', 5 of 100 μ l, 5 '-tetramethyl benzidine (TMB) matrix solution, and the lucifuge effect made it to carry out color reaction in 30 minutes under the room temperature, added the 0.18M sulphuric acid soln of 100 μ l at last, the color development stopping reaction.Read under wavelength 490nm, to read light absorption value in ELISA, and according to the concentration of typical curve conversion IL-6.
2. the making of typical curve
Advise according to the specification sheets that Endogen company provides, with 400 μ l analysis buffer dissolving IL-6 standard substance (mouse IL-6ELISA standard substance), making its concentration is the 2450pg/ milliliter, carry out 2.5 times of serial dilutions to the 38.4pg/ milliliter with analysis buffer again, measure the light absorption value of each concentration IL-6 standard substance under wavelength 490nm according to above-mentioned analytical procedure, the result is made into typical curve.
This research suppresses the preferable animal-origin milk-acid bacteria of Salmonellas at mouse, the serum of the liver organization of infection after 3 and 6 days is detected the TNF-alpha content, the result shows the mouse that only feeds PBS, can't suppress the Salmonellas intrusion, so the TNF-α output of its inflammation index obviously increases after infecting 6 days.LASW suppresses Salmonellas infiltration capability the best, so its TNF-alpha content that infects after 6 days is minimum; The detection of IL-6 also has identical result (Fig. 3).
Through the foregoing description and with reference to the accompanying drawings, should understand that the present invention is not limited among above-mentioned these embodiment.The person of ordinary skill in the field changes and improves when carrying out difference under the situation departing from specification sheets of the present invention and defined scope of claim and spirit not, also belongs in the category of the present invention.
Claims (10)
1. a Lactobacterium acidophilum (Lactobacillus acidophilus) LASW is characterized in that preserving number is CCTCC NO:M204083, is preserved in Chinese typical culture collection center.
2. Lactobacterium acidophilum LASW according to claim 1 is characterized in that having acid resistance.
3. Lactobacterium acidophilum LASW according to claim 1 is characterized in that having bile tolerance.
4. Lactobacterium acidophilum LASW according to claim 1 is characterized in that having the enteron aisle adsorptivity.
5. Lactobacterium acidophilum LASW according to claim 1 is characterized in that having the effect that suppresses pathogenic bacteria.
6. Lactobacterium acidophilum according to claim 1 is characterized in that this pathogenic bacteria is selected from the group that comprises that Salmonellas, intestinal bacteria, Shigellae, streptococcus aureus and Staphylococcus are formed.
7. Lactobacterium acidophilum LASW according to claim 1 is characterized in that having inhibition invasive pathogenic bacteria the effect that is transferred to liver and spleen is invaded in the absorption and the inhibition of intestinal cell.
8. a bacteria-promoting agent composition is characterized in that comprising the described Lactobacterium acidophilum LASW of claim 1.
9. a feed composition is characterized in that comprising the described Lactobacterium acidophilum LASW of claim 1.
10. a medical composition that prevents or treat pathogenic bacterial infection is characterized in that comprising the described Lactobacterium acidophilum LASW of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510105459A CN1940060B (en) | 2005-09-28 | 2005-09-28 | Lactobacillus acidophilus and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510105459A CN1940060B (en) | 2005-09-28 | 2005-09-28 | Lactobacillus acidophilus and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1940060A true CN1940060A (en) | 2007-04-04 |
| CN1940060B CN1940060B (en) | 2010-05-05 |
Family
ID=37958585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510105459A Expired - Fee Related CN1940060B (en) | 2005-09-28 | 2005-09-28 | Lactobacillus acidophilus and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1940060B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102559539A (en) * | 2011-12-02 | 2012-07-11 | 北京大北农科技集团股份有限公司 | Lactobacillus acidophilus and application thereof and feed additive thereof and premix compound thereof |
| CN103283973A (en) * | 2013-03-20 | 2013-09-11 | 广州格拉姆生物科技有限公司 | A method for producing a probiotic agent of live Lactobacillus acidophilus |
| CN104286408A (en) * | 2014-06-13 | 2015-01-21 | 杨雄 | Application method of biological agent prepared from Lactobacillus acidophilus XD13R on reducing proportion of drug-resistant bacteria in pet body |
| CN104415062A (en) * | 2013-08-27 | 2015-03-18 | 弘光科技大学 | Use of a cocktail comprising 4 strains of lactic acid bacteria for preventing and/or alleviating alcoholic liver disorders |
| CN104673726A (en) * | 2015-03-13 | 2015-06-03 | 北京市农林科学院 | Porcine lactobacillus acidophilus freeze-drying preparation and application thereof |
| CN104877946A (en) * | 2015-03-13 | 2015-09-02 | 成都医学院 | Excrement lactobacillus faecis FZB1 and application thereof |
| CN114395514A (en) * | 2022-02-28 | 2022-04-26 | 鲁东大学 | A strain of Lactobacillus acidophilus, bacterial agent and its application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953609A (en) * | 1974-02-06 | 1976-04-27 | Microlife Technics, Inc. | Method for the growth restriction of undesirable digestive system bacteria in animals and the establishment of lactobacillus lactis NRRL B-5628 |
| KR100324441B1 (en) * | 1999-02-08 | 2002-02-27 | 이은선 | Food for preventing gastritis, gastric and duodenal ulcers |
| CN100510055C (en) * | 2004-01-18 | 2009-07-08 | 北京三元食品股份有限公司 | Acidophilic lactobacillus and application thereof |
-
2005
- 2005-09-28 CN CN200510105459A patent/CN1940060B/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102559539A (en) * | 2011-12-02 | 2012-07-11 | 北京大北农科技集团股份有限公司 | Lactobacillus acidophilus and application thereof and feed additive thereof and premix compound thereof |
| CN102559539B (en) * | 2011-12-02 | 2015-04-15 | 北京大北农科技集团股份有限公司 | Lactobacillus acidophilus and application thereof and feed additive thereof and premix compound thereof |
| CN103283973A (en) * | 2013-03-20 | 2013-09-11 | 广州格拉姆生物科技有限公司 | A method for producing a probiotic agent of live Lactobacillus acidophilus |
| CN104415062A (en) * | 2013-08-27 | 2015-03-18 | 弘光科技大学 | Use of a cocktail comprising 4 strains of lactic acid bacteria for preventing and/or alleviating alcoholic liver disorders |
| CN104286408A (en) * | 2014-06-13 | 2015-01-21 | 杨雄 | Application method of biological agent prepared from Lactobacillus acidophilus XD13R on reducing proportion of drug-resistant bacteria in pet body |
| CN104673726A (en) * | 2015-03-13 | 2015-06-03 | 北京市农林科学院 | Porcine lactobacillus acidophilus freeze-drying preparation and application thereof |
| CN104877946A (en) * | 2015-03-13 | 2015-09-02 | 成都医学院 | Excrement lactobacillus faecis FZB1 and application thereof |
| CN104877946B (en) * | 2015-03-13 | 2018-01-30 | 成都医学院 | Excrement lactobacillus FZB1 and its application |
| CN114395514A (en) * | 2022-02-28 | 2022-04-26 | 鲁东大学 | A strain of Lactobacillus acidophilus, bacterial agent and its application |
| CN114395514B (en) * | 2022-02-28 | 2023-09-01 | 鲁东大学 | A strain of Lactobacillus acidophilus, bacterial agent and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1940060B (en) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Identification and probiotic potential of lactic acid bacteria from camel milk | |
| Barba-Vidal et al. | The probiotic combination of Bifidobacterium longum subsp. infantis CECT 7210 and Bifidobacterium animalis subsp. lactis BPL6 reduces pathogen loads and improves gut health of weaned piglets orally challenged with Salmonella Typhimurium | |
| Harnentis et al. | Novel probiotic lactic acid bacteria isolated from indigenous fermented foods from West Sumatera, Indonesia | |
| Karimi et al. | Antagonistic effect of isolated probiotic bacteria from natural sources against intestinal Escherichia coli pathotypes | |
| Afrin et al. | The prospects of lactobacillus oris as a potential probiotic with cholesterol-reducing property from mother's milk | |
| CN1819771A (en) | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal | |
| WO2021248440A1 (en) | Lactobacillus plantarum from breast milk and use thereof | |
| Josephs-Spaulding et al. | Human microbiome versus food-borne pathogens: friend or foe | |
| Tinrat et al. | In vitro assessment of Enterococcus faecalis MTC 1032 as the potential probiotic in food supplements | |
| Elavarasi et al. | Screening and characterization of Weissella cibaria isolated from food source for probiotic properties | |
| Jia et al. | Demonstration of safety characteristics and effects on gut microbiota of Lactobacillus gasseri HMV18 | |
| CN1940060A (en) | Novel lactic acidophilus and its application | |
| Idoui | Probiotic properties of Lactobacillus strains isolated from gizzard of local poultry | |
| KR101098946B1 (en) | Novel Lactobacillus salivarius strains and feed additive composition containing the same | |
| US9107938B2 (en) | Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads | |
| CN117904007B (en) | Bacillus subtilis strain SKLAN202311D and application thereof | |
| CN114437993A (en) | Lactobacillus reuteri and application thereof in preparation of preparation for preventing diarrhea in cats | |
| Li et al. | Dietary Enterococcus faecium NCIMB 11181 supplementation mitigates intestinal and systemic inflammation induced by avian pathogenic Escherichia coli O78 infection in broiler chickens | |
| Khongkool et al. | Characterization and Evaluation of Lactobacillus plantarum LC5. 2 Isolated from Thai Native Pigs for its Probiotic Potential in Gut Microbiota Modulation and Immune Enhancement | |
| CN115704002B (en) | A kind of Clostridium butyricum CC02001 and its application | |
| Kenar et al. | The determination of antimicrobial and antibiofilm activities of foodborne lactic acid bacteria against Enterobacter cloacae isolates | |
| Barzegar et al. | Antibacterial Effects of Compound Bifilact on E. coli and Campylobacter jejuni. | |
| Sipahi | Investigation of antagonistic effect of probiotic food supplement against different strains of bacteria | |
| Liu et al. | Isolation and characterization of potential Lactobacillus acidophilus strains isolated from pig feces | |
| TW201809263A (en) | Immunnomodulatory Lactobacillus plantarumand use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100505 Termination date: 20100928 |